Adimmune Corporation (4142) announced today at its investor conference that the company has implemented operational adjustments in response to shifting global political and economic circumstances. In the first half of this year, Adimmune successfully passed inspections by Brazilian ANVISA and EMA respectively. To meet growing demand from clients for additional production capacity, the company’s existing facilities are operating at full load. Adimmune has therefore initiated the installation of a third automated aseptic filling line with an annual capacity of 4 million doses, designed to serve customized, small-batch, and high-value products, and provide end-to-end services from clinical trials to commercial manufacturing—enhancing both capacity and scheduling flexibility.   

In strengthening its process and product development, Adimmune continues to implement Quality by Design (QbD) principles—integrating process design from preclinical stages through post-market to align with global standards. This initiative has already yielded results: the company has scheduled a second filling line to serve U.S. and European markets for a major global client. Line equipment was installed in the first half of the year, with trial production targeted by year-end, aiming to double supply volumes in 2026.   

In the biosimilar drug segment, Adimmune completed commercial batch production for Asian and North American markets in the first half of the year and has passed EMA inspections. Full-scale commercial production will commence in the third quarter, with capacity expansion planned by year-end to meet the demand.   

The company has also been engaged to start developing next-generation emerging infectious disease vaccines. Equipment procurement has been completed and technology transfer has been initiated, with the aim of completing process validation batches for the U.S. and European markets next year.   

In its EV71 (Enterovirus 71) vaccine business targeting ASEAN markets, Adimmune’s subsidiary, Enimmune Corp., has filed for marketing authorization in Macau, Vietnam, and Thailand. Enimmune is also collaborating with Vietnam’s largest state-owned vaccine producer. To meet the demand in Southeast Asia, Adimmune’s Tanzi cell culture facility has scaled up production from 50 liters to 200 liters, with plans to further expand to 1,000 liters. This expansion will also support CDMO projects for other international biologics manufacturers, with an estimated capacity ranging from millions to tens of millions of doses annually.   

Domestically, Adimmune remains the primary supplier of government-funded seasonal influenza vaccines this autumn/winter, and has completed the production this year.